Genmab — Marts 2025
-
-
Rova-T: the story of AbbVie’s multi-billion dollar failure -I'll have another look at this story tomorrow, but maybe this is also about AbbVie having a grudge with former Stemcentrx employees... https://www.science.org/content/blog-post/last-stemcentrx
-
Abbvie tabte en meget ligende sag mod Adcentrx. Dommeren afviste sagen grundet manglende beviser på en kriminel handling. https://casetext.com/case/abbvie-inc-v-adcentrx-therapeutics-inc?utm_source=chatgpt.com&__cf_chl_rt_tk=6cLBbJCdxo3.l47PVnxvbN5nCD55gIk5u605i6EDfmg-1742847322-1.0.1.1-dnnmMeqSOFS.oHThbMIG.pnL8_CO9u_dEtkfHwXHyc8
-
Store fremskridt i behandling af knoglemarvskræft https://www.myelomatose.dk/nyheder/store-fremskridt-i-behandling-af-knoglemarvskraeft/
-
Bolt Biotherapeutics Reports Full-Year 2024 Financial Results https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2024 - The Company continues to work with Genmab to discover and develop next-generation ISACs for the treatment of cancer. Genmab and the Company are working together to advance the collaboration’s first development candidate, and the collaboration also continues research and development on additional programs.
-
-
AbbVie and Genmab: Can a legal battle break a billion-dollar bond? https://www.labiotech.eu/trends-news/abbvie-genmab-lawsuit/
-
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta
in people with relapsing multiple sclerosis
Mar 25, 2025 https://www.novartis.com/news/media-releases/novartis-present-new-data-aan-including-seven-year-disability-outcomes-and-safety-analysis-kesimpta-people-relapsing-multiple-sclerosis -
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer https://www.cancernetwork.com/view/rina-s-elicited-responses-with-without-fr-expression-in-ovarian-cancer
-
E L, thank you very much for the link10.08. The article provides relevant perspective on AbbVie's lawsuit against Genmab.
-
Does it worry you too, that Gmab is not arguing they come up with idea of using disaccharides to enhance the hydrophilicity. Rather they claim, "according to Genmab, AbbVie has never pursued the development of products using the alleged trade secrets — nor sought to protect them through patents. In Genmab’s view, this raises questions about whether AbbVie is now trying to assert control over innovations it neither commercialized nor legally secured.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind